- Home
- NDRA vs QLGN Comparison
NDRA vs QLGN Comparison
Compare NDRA & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDRA
- QLGN
- Stock Information
- Founded
- NDRA 2007
- QLGN 1996
- Country
- NDRA United States
- QLGN United States
- Employees
- NDRA N/A
- QLGN N/A
- Industry
- NDRA Biotechnology: Electromedical & Electrotherapeutic Apparatus
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- NDRA Health Care
- QLGN Health Care
- Exchange
- NDRA Nasdaq
- QLGN Nasdaq
- Market Cap
- NDRA 2.1M
- QLGN 2.2M
- IPO Year
- NDRA 2017
- QLGN N/A
- Fundamental
- Price
- NDRA $3.98
- QLGN $3.48
- Analyst Decision
- NDRA Strong Buy
- QLGN
- Analyst Count
- NDRA 1
- QLGN 0
- Target Price
- NDRA $50.00
- QLGN N/A
- AVG Volume (30 Days)
- NDRA 355.0K
- QLGN 158.4K
- Earning Date
- NDRA 05-13-2025
- QLGN 05-06-2025
- Dividend Yield
- NDRA N/A
- QLGN N/A
- EPS Growth
- NDRA N/A
- QLGN N/A
- EPS
- NDRA N/A
- QLGN N/A
- Revenue
- NDRA N/A
- QLGN N/A
- Revenue This Year
- NDRA N/A
- QLGN N/A
- Revenue Next Year
- NDRA N/A
- QLGN N/A
- P/E Ratio
- NDRA N/A
- QLGN N/A
- Revenue Growth
- NDRA N/A
- QLGN N/A
- 52 Week Low
- NDRA $2.97
- QLGN $2.85
- 52 Week High
- NDRA $665.00
- QLGN $29.45
- Technical
- Relative Strength Index (RSI)
- NDRA 51.65
- QLGN 52.85
- Support Level
- NDRA $3.28
- QLGN $3.10
- Resistance Level
- NDRA $3.98
- QLGN $4.40
- Average True Range (ATR)
- NDRA 0.92
- QLGN 0.40
- MACD
- NDRA 0.02
- QLGN 0.05
- Stochastic Oscillator
- NDRA 31.76
- QLGN 40.32
About NDRA ENDRA Life Sciences Inc.
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI at the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.